MANNKIND CORP Cost of Revenue
MANNKIND CORP (MNKD) reported Cost of Revenue of $14.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- MANNKIND CORP cost of goods and services sold for the quarter ending 2026-06-30 was $14.41M, a 212.76% increase year-over-year.
- MANNKIND CORP cost of goods and services sold for the quarter ending 2026-03-31 was $7.51M, a 99.28% increase year-over-year.
- MANNKIND CORP cost of goods and services sold for the quarter ending 2025-12-31 was $13.93M, a 189.66% increase year-over-year.
- MANNKIND CORP cost of goods and services sold for the quarter ending 2025-09-30 was $4.50M, a 40.69% increase year-over-year.
- MANNKIND CORP cost of goods and services sold for fiscal 2025 was $26.80M, a 53.77% increase from fiscal 2024.
- MANNKIND CORP cost of goods and services sold for fiscal 2024 was $17.43M, a 16.46% decline from fiscal 2023.
- MANNKIND CORP cost of goods and services sold for fiscal 2023 was $20.86M, a 30.37% increase from fiscal 2022.
- MANNKIND CORP cost of goods and services sold for fiscal 2022 was $16.00M, a 4.93% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $14.41M 10-Q · filed 2026-08-05 | $21.92M 10-Q · filed 2026-08-05 | $35.84M derived: sum of 3 quarters · filed 2026-08-05 | $40.34M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $7.51M 10-Q · filed 2026-05-06 | $21.44M derived: sum of 2 quarters · filed 2026-05-06 | $25.93M derived: sum of 3 quarters · filed 2026-05-06 | $30.54M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $13.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.43M derived: sum of 2 quarters · filed 2026-02-26 | $23.03M derived: sum of 3 quarters · filed 2026-08-05 | $26.80M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $4.50M 10-Q · filed 2025-11-05 | $9.11M derived: sum of 2 quarters · filed 2026-08-05 | $12.87M 10-Q · filed 2025-11-05 | $17.68M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $4.61M 10-Q · filed 2026-08-05 | $8.38M 10-Q · filed 2026-08-05 | $13.18M derived: sum of 3 quarters · filed 2026-08-05 | $16.38M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $3.77M 10-Q · filed 2026-05-06 | $8.58M derived: sum of 2 quarters · filed 2026-05-06 | $11.77M derived: sum of 3 quarters · filed 2026-05-06 | $17.38M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.01M derived: sum of 2 quarters · filed 2026-02-26 | $13.61M derived: sum of 3 quarters · filed 2026-02-26 | $17.43M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $3.20M 10-Q · filed 2025-11-05 | $8.80M derived: sum of 2 quarters · filed 2025-11-05 | $12.62M 10-Q · filed 2025-11-05 | $18.73M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $5.61M 10-Q · filed 2025-08-06 | $9.42M 10-Q · filed 2025-08-06 | $15.54M derived: sum of 3 quarters · filed 2026-02-26 | $19.53M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $3.82M 10-Q · filed 2025-05-08 | $9.93M derived: sum of 2 quarters · filed 2026-02-26 | $13.93M derived: sum of 3 quarters · filed 2026-02-26 | $19.15M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.11M derived: sum of 2 quarters · filed 2026-02-26 | $15.33M derived: sum of 3 quarters · filed 2026-02-26 | $20.86M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $4.00M 10-Q · filed 2024-11-07 | $9.22M derived: sum of 2 quarters · filed 2024-11-07 | $14.75M 10-Q · filed 2024-11-07 | $18.83M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $5.22M 10-Q · filed 2024-08-07 | $10.75M 10-Q · filed 2024-08-07 | $14.84M derived: sum of 3 quarters · filed 2025-02-26 | $19.86M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $5.53M 10-Q · filed 2024-05-08 | $9.61M derived: sum of 2 quarters · filed 2025-02-26 | $14.63M derived: sum of 3 quarters · filed 2025-02-26 | $19.25M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $9.10M derived: sum of 2 quarters · filed 2025-02-26 | $13.72M derived: sum of 3 quarters · filed 2025-02-26 | $16.00M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $5.02M 10-Q · filed 2023-11-07 | $9.64M derived: sum of 2 quarters · filed 2023-11-07 | $11.92M 10-Q · filed 2023-11-07 | $16.22M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $4.62M 10-Q · filed 2023-08-07 | $6.90M 10-Q · filed 2023-08-07 | $11.20M derived: sum of 3 quarters · filed 2024-02-27 | $15.01M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $2.28M 10-Q · filed 2023-05-09 | $6.58M derived: sum of 2 quarters · filed 2024-02-27 | $10.39M derived: sum of 3 quarters · filed 2024-02-27 | $14.80M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $8.11M derived: sum of 2 quarters · filed 2024-02-27 | $12.52M derived: sum of 3 quarters · filed 2024-02-27 | $16.83M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $3.81M 10-Q · filed 2022-11-08 | $8.22M derived: sum of 2 quarters · filed 2022-11-08 | $12.54M 10-Q · filed 2022-11-08 | $16.19M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $4.41M 10-Q · filed 2022-08-09 | $8.73M 10-Q · filed 2022-08-09 | $12.38M derived: sum of 3 quarters · filed 2023-02-23 | $15.97M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $4.32M 10-Q · filed 2022-05-05 | $7.97M derived: sum of 2 quarters · filed 2023-02-23 | $11.56M derived: sum of 3 quarters · filed 2023-02-23 | $15.23M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $7.24M derived: sum of 2 quarters · filed 2023-02-23 | $10.92M derived: sum of 3 quarters · filed 2023-02-23 | $15.08M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $3.59M 10-Q · filed 2021-11-09 | $7.27M derived: sum of 2 quarters · filed 2021-11-09 | $11.43M 10-Q · filed 2021-11-09 | $16.06M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $3.68M 10-Q · filed 2021-08-11 | $7.84M 10-Q · filed 2021-08-11 | $12.47M derived: sum of 3 quarters · filed 2021-08-11 | $19.57M derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $4.16M 10-Q · filed 2021-05-12 | $8.80M derived: sum of 2 quarters · filed 2021-05-12 | $15.89M derived: sum of 3 quarters · filed 2021-05-12 | $20.22M derived: sum of 4 quarters · filed 2021-05-12 | |
| 2019-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $11.73M derived: sum of 2 quarters · filed 2021-02-25 | $16.06M derived: sum of 3 quarters · filed 2021-02-25 | $20.08M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $7.10M 10-Q · filed 2020-11-04 | $11.43M derived: sum of 2 quarters · filed 2020-11-04 | $15.45M 10-Q · filed 2020-11-04 | $20.43M derived: sum of 4 quarters · filed 2020-11-04 | |
| 2019-06-30 | $4.33M 10-Q · filed 2020-08-05 | $8.35M 10-Q · filed 2020-08-05 | $13.33M derived: sum of 3 quarters · filed 2020-08-05 | $18.64M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-31 | $4.02M 10-Q · filed 2020-05-06 | $9.01M derived: sum of 2 quarters · filed 2020-05-06 | $14.31M derived: sum of 3 quarters · filed 2020-05-06 | $19.40M derived: sum of 4 quarters · filed 2020-05-06 | |
| 2018-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $10.29M derived: sum of 2 quarters · filed 2020-02-25 | $15.38M derived: sum of 3 quarters · filed 2020-02-25 | $19.39M 10-K · filed 2020-02-25 | $19.40M 10-K · filed 2019-02-26 |
| 2018-09-30 | $5.30M 10-Q · filed 2019-11-08 | $10.40M derived: sum of 2 quarters · filed 2019-11-08 | $14.41M 10-Q · filed 2019-11-08 | $19.42M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2018-06-30 | $5.09M 10-Q · filed 2019-08-07 | $9.10M 10-Q · filed 2019-08-07 | $14.12M derived: sum of 3 quarters · filed 2019-08-07 | $18.70M derived: sum of 4 quarters · filed 2019-08-07 | |
| 2018-03-31 | $4.01M 10-Q · filed 2019-05-07 | $9.03M derived: sum of 2 quarters · filed 2019-05-07 | $13.60M derived: sum of 3 quarters · filed 2019-05-07 | $18.69M derived: sum of 4 quarters · filed 2019-05-07 | |
| 2017-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $9.59M derived: sum of 2 quarters · filed 2019-02-26 | $14.68M derived: sum of 3 quarters · filed 2019-02-26 | $17.23M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $4.58M 10-Q · filed 2018-11-01 | $9.66M derived: sum of 2 quarters · filed 2018-11-01 | $12.21M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $5.09M 10-Q · filed 2018-08-02 | $7.63M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $17.12M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |